Clinical Trial: Physiologic Insulin Resensitization (PIR) Treatment in Patients With a Diagnosis of Type 2 Diabetes Mellitus (T2DM)

U.S., Oct. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07906470) titled 'Physiologic Insulin Resensitization (PIR) Treatment in Patients With a Diagnosis of Type 2 Diabetes Mellitus (T2DM)' on Sept. 30.

Brief Summary: The purpose of the study is to assess the outcomes of Physiologic Insulin Resensitization (PIR) treatment compared to standard of care (SOC) on patients with a diagnosis of Type 2 diabetes mellitus (T2DM). Participants will be in this study for 24 to 26 weeks.

Study Start Date: Oct. 26

Study Type: INTERVENTIONAL

Condition: Type 2 Diabetes Mellitus

Intervention: OTHER: Physiologic insulin resensitization (PIR)

The PIR group will be required to undergo a three-hour infusion of insulin ...